Antisense approaches to cancer gene therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Antisense agents, including oligodeoxynucleotides and plasmid-derived RNA, are crucial for cancer gene therapy.
• Recent advancements focus on agents and systems progressing to clinical trials or showing tumor regression in animal models.

Purpose of the Study:

• To summarize recent progress in oligodeoxynucleotide and plasmid-derived RNA antisense agents for cancer gene therapy.
• To highlight agents and systems that have advanced to clinical trials or demonstrated efficacy in preclinical models.

Main Methods:

• Utilizing transformed cell lines with plasmids/viruses for antisense RNA transcription for in vivo studies.
• Investigating oligodeoxynucleotide applications in whole animals and clinical trials.
• Comparing results from oligodeoxynucleotide and plasmid-derived antisense RNA targeting the same genes.
• Examining antisense effects in syngeneic and immunocompetent hosts.

Main Results:

• Transformed cell lines facilitate thorough characterization of antisense RNA effects on gene expression and phenotype.
• Promising results from cell culture studies support the in vivo application of oligodeoxynucleotides.
• Concordant results observed for both oligodeoxynucleotide and plasmid-derived antisense RNA against common targets.
• Tumor regression and protection against tumor formation observed in studies of insulin-like growth factor and its receptor.

Conclusions:

• Antisense agents, particularly oligodeoxynucleotides and plasmid-derived RNA, hold significant potential for cancer gene therapy.
• Preclinical successes are paving the way for broader clinical applications.
• In vivo validation in relevant host models is critical for assessing therapeutic efficacy.